Entrada Therapeutics (TRDA) Income towards Parent Company (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Income towards Parent Company of -$39.7 million for Q1 2026, down 128.93% year-over-year from $137.3 million in Q1 2025, and down 1.39% quarter-over-quarter from -$39.2 million in Q4 2025.
Entrada Therapeutics (TRDA) Income towards Parent Company (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$39.7 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 128.93% year-over-year to -$39.7 million; the TTM figure through Mar 2026 stood at -$166.1 million (down 771.6% YoY), while the FY2025 annual figure was -$143.7 million, down 319.01% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$39.7 million, down from -$39.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was $55.0 million in Q2 2024, with the low at -$44.1 million in Q3 2025.
- The 5-year median for Income towards Parent Company is -$21.7 million (2022), against an average of -$12.9 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company soared 452.05% in 2024, then plunged 3563.48% in 2025.
- Entrada Therapeutics' Income towards Parent Company stood at -$24.6 million in 2022, then surged by 61.42% to -$9.5 million in 2023, then surged by 111.9% to $1.1 million in 2024, then slumped by 3563.48% to -$39.2 million in 2025, then declined by 1.39% to -$39.7 million in 2026.
- Business Quant data shows TRDA's Income towards Parent Company at -$39.7 million in Q1 2026, -$39.2 million in Q4 2025, and -$44.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.76 Mn |
| Mar 31, 2026 | -39.72 Mn |
| Dec 31, 2025 | -39.17 Mn |
| Sep 30, 2025 | -44.13 Mn |
| Jun 30, 2025 | -43.13 Mn |
| Mar 31, 2025 | -17.35 Mn |
| Dec 31, 2024 | 1.13 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | 54.99 Mn |
| Mar 31, 2024 | 23.50 Mn |
| Dec 31, 2023 | -9.50 Mn |
| Sep 30, 2023 | 35.46 Mn |
| Jun 30, 2023 | -25.93 Mn |
| Mar 31, 2023 | -6.67 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -25.14 Mn |
| Jun 30, 2022 | -23.18 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -47.36 Mn |
| Sep 30, 2021 | -34.46 Mn |